HUTCHMED

FY23 results point to strong financials and fundamentals

Lighthouse | 29 February 2024

Share this note

  • HUTCHMED management have described 2023 as an ‘exceptional year’. The company made significant progress in executing on its strategy to become sustainably profitable from FY25, and on advancing its pipeline. The latter has 15+ registration/registration-intent studies in progress with seven drug candidates, but it was the FDA approval and US launch of first global product FRUZAQLA (fruquintinib) that was the standout achievement.
  • The Takeda fruquintinib deal for global ex-China rights made a major contribution to FY23 revenues. Receipt of the $400m upfront and a $35m US approval milestone (with $280m and $32m recognised in FY23, respectively) helped HUTCHMED achieve the upper end of its $450-550m FY23 Oncology/Immunology segment guidance. Impressively, FRUZAQLA generated $15.1m of in-market sales post US approval in November 2023.
  • FY23 consolidated Oncology/Immunology segment revenues grew +228% CER to $528.6m (FY22: $163.8m), which included product-related revenues of $164.2m (FY22: $124.6m), R&D services of $52.4m (FY22: $24.2m), and $312m (FY22: $15m) from partnering income. In-market oncology product sales grew +35% CER to $231.6m (FY22: $167.1m). Total FY23 revenues were $838m (+102% CER, FY22: $426.4m), including Other Ventures income of $309.4m (+18%, FY22: $262.6m). End-FY23 cash was $886m, boosted by Takeda income (end-H123: $856m, end-FY22: $631m).
  • Completion of several large late-stage trials and the impact of the portfolio optimisation reduced R&D expenses considerably, by 22% to $302.0m (FY22: $386.9m). Restructuring of US operations contributed to lower SG&A of $133.2m (FY22: $136.1m) despite expansion of oncology hospital and physician coverage in China. Net income from Other Items of $82.4m (vs $46.9m) reflected higher interest income on the Takeda upfront. Net income was $100.8m (FY22: Net Loss $360.8m), likely a temporary profit until FY25.
  • HUTCHMED’s outlook is for continued strong product revenue growth, coupled with reduced expenses. FY24 Oncology/Immunology consolidated revenue guidance is $300-$400m, driven by targeted 30-50% growth in marketed product sales and royalties.

Trinity Delta view: HUTCHMED’s path to profitability continues to be supported by solid commercial execution in China, the prospect of additional approvals and launches in China and globally, and a solid balance sheet. Several pipeline assets could reach the market by 2025, including other global fruquintinib launches by Takeda (Europe and Japan regulatory decisions in advanced mCRC are anticipated in 2024); fruquintinib indication expansion in China (2L gastric cancer filed; potential 2024-25 filings for 2L EMC and 2L RCC); potential China approval of the first immunology asset sovleplenib in 2L immune thrombocytopenia (ITP) (under priority review in China), in which there is growing interest, and potential for global savolitinib filings by partner AstraZeneca in Tagrisso-refractory NSCLC around end-2024. Our last published valuation was $5.74bn/ £4.78bn/ HK$44.75bn, or $32.95/ADS and 549p/HK$51.40 per share.

Lighthouse

29 February 2024

Price (US ADS)
(UK share)
(SEHK share)
US$15.21
244.0p
HK$24.20
Market Cap
 
US$2.75bn
£2.17bn
HK$21.08bn
ExchangesNASDAQ
AIM London
SEHK
SectorHealthcare
Company CodesHCM
HCM.L
0013.HK
Corporate clientYes

Company description

HUTCHMED is a Hong Kong headquartered biopharma focused on discovering, developing and commercializing innovative targeted therapeutics and immunotherapies to treat cancer and autoimmune diseases. It has a diverse pipeline of first-in-class/best-in-class selective oral TKIs in development for the China and global markets.

Analysts

Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner
pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Disclaimer

Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.